AML Cell Immunotherapy Using Chimeric Antigen Receptor T-cells (CAR-LAM)

Centre Hospitalier Universitaire de Besancon

Status: Completed

Conditions: Acute Myeloid Leukemia

Treatments: Other: Sample collection

Study type: Interventional

Funder types: Other

Identifiers

NCT04169022

P/2018/402

Details and patient eligibility

About

AML is one of the most aggressive forms of leukemia, where bone marrow transplantation remains the gold standard treatment, with its known associated toxicities and related mortality. Despite progress in the treatment of leukemic malignancies, especially the emergence of targeted- and immuno-therapies arising from biological genomic knowledge, there remains a need to provide additional strategies for refractory/relapsing (R/R) patients

Aim of this study is to collect biological samples of AML patients in order to validate our Chimeric Antigen Receptor T-cells immunotherapy approach

Enrollment: 86 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• AML patients adults and pediatrics

Exclusion criteria

• AML3

Trial design

Primary purpose: Screening

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

86 participants in 2 patient groups

AML patients at diagnosis

Experimental group

Description:

AML patients at diagnosis (except AML3)

Treatment:

Other: Sample collection

AML patients at relapse

Experimental group

Description:

AML patients at relapse after chemotherapy, targeted therapy or allograft

Treatment:

Other: Sample collection